Hepatology:变异体在晚期转移性肝癌中起重要作用

2012-11-29 Hepatology Hepatology

来自武汉大学医学院、武汉大学人民医院以及江西赣南医学院的研究人员近日在新研究中证实KIAA0101变异体1(KIAA0101 tv1)在晚期转移性肝癌中起重要作用,通过调控p53功能促进了肝癌细胞生存。相关论文发表在国际著名肝脏疾病杂志Hepatology上。 武汉大学医学院的朱帆(Fan Zhu)为这篇论文的通讯作者。其研究方向是“逆转录病毒感染引发精神分裂症的分子机制研究”以及“HB

来自武汉大学医学院、武汉大学人民医院以及江西赣南医学院的研究人员近日在新研究中证实KIAA0101变异体1(KIAA0101 tv1)在晚期转移性肝癌中起重要作用,通过调控p53功能促进了肝癌细胞生存。相关论文发表在国际著名肝脏疾病杂志Hepatology上。
 
武汉大学医学院的朱帆(Fan Zhu)为这篇论文的通讯作者。其研究方向是“逆转录病毒感染引发精神分裂症的分子机制研究”以及“HBx/癌基因相互作用致癌相关性基因的克隆及其功能性研究”。
 
根据世界卫生组织(WHO)公布的资料显示在过去10年间全球癌症的发病率及死亡率增长了22%,其中肝癌无论从发病率还是死亡率来看,均为全球对人类身体健康危害最大的癌症之一。尤其在东亚和非洲。在我国,肝癌是发病率仅次于胃癌的高发癌症。肝癌和其它肿瘤一样是遗传和环境等诸多因素的相互作用所致,涉及大量相关基因的结构和表达调控的改变。鉴别与肝癌相关的基因对于深入了解肝病发病及病程机制,开发潜在的治疗策略具有重要的意义。
  
过去的研究表明在甲状腺癌、结肠癌和非小细胞肺癌等多种恶性实体瘤中都检测到在mRNA水平上有KIAA0101的异常表达表达,且与肿瘤进程相关。然而对于KIAA0101表达水平与人类肝癌(HCC)之间的关系却存在有争议。
 
在这篇文章中,研究人员通过半定量逆转录-聚合酶链反应 (Reverse Transcription-Polymerase Chain Reaction,RT- PCR)、虚拟northern印迹法、western印迹法以及免疫组织化学分析证实在肝癌组织和细胞系中,尤其是3-4期肝癌的KIAA0101转录变异体1 (KIAA0101 tv1)在mRNA和蛋白质水平上均存在异常表达。用KIAA0101 tv1转染NIH3T3细胞诱导了体外克隆形成以及体内移植肿瘤,表明KIAA0101 tv1具有致癌潜能。半定量RT-PCR、实时定量RT-PCR和western blot分析证实阿霉素治疗下调了KIAA0101 tv1的表达,转而增强了p53蛋白的乙酰化作用。而KIAA0101 tv1可以通过抑制p53 Lys382位点乙酰化阻止阿霉素诱导的凋亡。免疫沉淀分析和哺乳动物双杂交分析表明KIAA0101 tv1结合到了p53的反式激活区域(1-42氨基酸),强有力地抑制了它的转录活性。
 
新研究数据表明KIAA0101 tv1在晚期转移性肝癌中起重要作用,通过抑制p53基因的转录活性阻止了化疗药物治疗诱导的凋亡。这些结果表明KIAA0101 tv1有可能通过调控p53功能促进了肝癌细胞生存。抑制KIAA0101 tv1功能有可能是一种开发新型癌症治疗药物的有希望的新策略。


Abstract
KIAA0101 overexpression was detected in numerous malignant solid tumors and involved in tumor progression; however, the correlation between KIAA0101 expression level and human hepatocellular carcinoma (HCC) was controversial. Our data revealed abnormal expression of the KIAA0101 transcript variant 1 (KIAA0101 tv1) at both messenger RNA and protein levels in HCC tissues and cell lines assessed by semiquantitative reverse-transcription polymerase chain reaction (RT-PCR), virtual northern blot, western blot, and immunohistochemical analysis, especially in stage 3-4 HCCs. NIH3T3 cells transfected with KIAA0101 tv1 induced colony formation in vitro and tumor xenorafts in vivo, implying the oncogenic potential of KIAA0101 tv1. Semiquantitative RT-PCR, real-time quantitative RT-PCR, and western blot analysis demonstrated that doxorubicin (Adriamycin, ADR) treatment down-regulated expression of the KIAA0101 tv1, whereas it increased the acetylation of the p53 protein. Additionally, KIAA0101 tv1 prevented cells from apoptosis caused by ADR through suppressing the acetylation of p53 at Lys382. Immunoprecipitation analysis and mammalian two-hybrid assay indicated that KIAA0101 tv1 bound to the transactivation region (1-42 amino acids) of p53 and strongly inhibits its transcriptional activity. Taken together, our data suggest that KIAA0101 tv1 played an important role in the late stage of metastatic HCC and prevented apoptosis after chemotherapeutic drug treatment through inhibiting the transcriptional activity of the p53 gene. Conclusion: KIAA0101 tv1 may function as a regulator, promoting cell survival in HCC through regulating the function of p53. Suppression of the KIAA0101 tv1 function is likely to be a promising strategy to develop novel cancer therapeutic drugs. (Hepatology 2012;56:1760–1769)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1951285, encodeId=0327195128519, content=<a href='/topic/show?id=a85338105b8' target=_blank style='color:#2F92EE;'>#变异体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38105, encryptionId=a85338105b8, topicName=变异体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sun Oct 20 07:50:00 CST 2013, time=2013-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023452, encodeId=0295202345264, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Apr 24 16:50:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342260, encodeId=78301342260a3, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Dec 01 06:50:00 CST 2012, time=2012-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386085, encodeId=f4eb1386085f6, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Dec 01 06:50:00 CST 2012, time=2012-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426513, encodeId=05e6142651365, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Dec 01 06:50:00 CST 2012, time=2012-12-01, status=1, ipAttribution=)]
    2013-10-20 chenwq08
  2. [GetPortalCommentsPageByObjectIdResponse(id=1951285, encodeId=0327195128519, content=<a href='/topic/show?id=a85338105b8' target=_blank style='color:#2F92EE;'>#变异体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38105, encryptionId=a85338105b8, topicName=变异体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sun Oct 20 07:50:00 CST 2013, time=2013-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023452, encodeId=0295202345264, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Apr 24 16:50:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342260, encodeId=78301342260a3, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Dec 01 06:50:00 CST 2012, time=2012-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386085, encodeId=f4eb1386085f6, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Dec 01 06:50:00 CST 2012, time=2012-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426513, encodeId=05e6142651365, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Dec 01 06:50:00 CST 2012, time=2012-12-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1951285, encodeId=0327195128519, content=<a href='/topic/show?id=a85338105b8' target=_blank style='color:#2F92EE;'>#变异体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38105, encryptionId=a85338105b8, topicName=变异体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sun Oct 20 07:50:00 CST 2013, time=2013-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023452, encodeId=0295202345264, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Apr 24 16:50:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342260, encodeId=78301342260a3, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Dec 01 06:50:00 CST 2012, time=2012-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386085, encodeId=f4eb1386085f6, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Dec 01 06:50:00 CST 2012, time=2012-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426513, encodeId=05e6142651365, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Dec 01 06:50:00 CST 2012, time=2012-12-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1951285, encodeId=0327195128519, content=<a href='/topic/show?id=a85338105b8' target=_blank style='color:#2F92EE;'>#变异体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38105, encryptionId=a85338105b8, topicName=变异体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sun Oct 20 07:50:00 CST 2013, time=2013-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023452, encodeId=0295202345264, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Apr 24 16:50:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342260, encodeId=78301342260a3, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Dec 01 06:50:00 CST 2012, time=2012-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386085, encodeId=f4eb1386085f6, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Dec 01 06:50:00 CST 2012, time=2012-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426513, encodeId=05e6142651365, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Dec 01 06:50:00 CST 2012, time=2012-12-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1951285, encodeId=0327195128519, content=<a href='/topic/show?id=a85338105b8' target=_blank style='color:#2F92EE;'>#变异体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38105, encryptionId=a85338105b8, topicName=变异体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sun Oct 20 07:50:00 CST 2013, time=2013-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023452, encodeId=0295202345264, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Apr 24 16:50:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342260, encodeId=78301342260a3, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Dec 01 06:50:00 CST 2012, time=2012-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386085, encodeId=f4eb1386085f6, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Dec 01 06:50:00 CST 2012, time=2012-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426513, encodeId=05e6142651365, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Dec 01 06:50:00 CST 2012, time=2012-12-01, status=1, ipAttribution=)]
    2012-12-01 gwc384

相关资讯

Hepatology:抑癌因子控制了非酒精性脂肪性肝炎的发展

近日,来自日本庆应义塾大学医学院的研究人员发现,在人类及老鼠体内,p53/p66Shc介导的信号促进了非酒精性脂肪性肝炎(NASH)的发展。相关研究成果于5月28日在线发表在Journal of Hepatology上。 p53基因是一种抑癌基因,是细胞生长周期中的负调节因子,与细胞周期的调控、DNA修复、细胞分化、细胞凋亡等重要的生物学功能有关。p53基因的突变(缺失)是人类肿瘤的常见事件,与

Hepatology:CXCL5介导中性粒细胞浸润促进肝癌转移

趋化因子是能使细胞发生趋化运动的小分子细胞因子,分子量多在8-14kDa之间。趋化因子与趋化因子受体结合后传递多种细胞信息。CXCL5是一个小分子类型的分泌蛋白,属于趋型趋化因子家族成员。近来,CXCL5与癌症发生发展的相关证据已经有很多。 最近,为了研究CXCL5在肝细胞癌的生长、侵袭和预后中的作用,研究人员研究了具有不同转移性能的人肝癌细胞系以及919例肝癌患者中CXCL5的mRNA和蛋白水